What is already known about this topic?
Little is known about vaccine effectiveness (VE) of different booster strategies following Ad.26.COV2.S (Janssen [Johnson & Johnson]) vaccination, especially during Omicron variant predominance.
What is added by this report?
VE against COVID-19–associated emergency department/urgent care visits was 24% after 1 Jansen dose, 54% after 2 Jansen doses, and 79% after 1 Janssen/1 mRNA dose, compared to 83% after 3 mRNA doses. VE for the same strategies against COVID-19–associated hospitalization was 31%, 67%, 78%, and 90% respectively.
What are the implications for public health practice?
All eligible persons should receive recommended COVID-19 booster doses to prevent moderate to severe COVID-19. Adult Janssen primary vaccine recipients should preferentially receive a heterologous mRNA vaccine booster dose ≥2 months later.
Entire content available on: https://www.cdc.gov/mmwr/volumes/71/wr/mm7113e2.htm
Lingua
IngleseTipologia
Articoli scientifici/ReviewsArgomento
Covid-19 VacciniProfilo
Salute pubblicaPaese
USA